Strategic collaboration combines Nurix’s leadership in targeted protein degradation with Roche’s portfolio of B-cell targeted therapies and ...
Northwestern Medicine scientists have developed a novel synthetic biomolecular condensate that can degrade intracellular ...
Can you please introduce yourself and your role at LifeArc? As part of my Biochemistry degree at University of Leeds, I completed an industry placement at LifeArc. This was my first introduction to ...
A new active substance attacks a key protein in tumor cells, leading to complete degradation. In cell experiments, this caused cancer cells to lose their protection and die. The active substance was ...
Targeted protein degradation has moved well beyond its prologue more than 20 years ago. 1 The number of publications describing different PROTACs (PROteolysis TArgeting Chimeras), molecular glues, and ...
The end of the undruggable: Targeted protein degradation therapies open new frontiers in cancer care
Targeted protein degradation (TPD) therapy is a promising new class of targeted treatments. Based on a cell’s natural mechanism for eliminating diseased proteins, this therapy can combat hard-to-treat ...
An illustration of one of Grove Biopharma’s protein-like polymers in sky blue and bright yellow. These protein-like polymers may help target intractable cancer-causing proteins. Credit: Saeed Najafi, ...
Targeted protein degradation (TPD) therapeutics seek to harness this intrinsic quality control machinery to selectively ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results